CVE:COT Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis → Will this AI Micro-Cap be Bigger than NVIDIA? (From Behind the Markets) (Ad) Free COT Stock Alerts C$0.04 -0.03 (-41.67%) (As of 10/14/2020) Add Compare Share Share Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0452-Week RangeC$0.02▼C$0.12Volume1,000 shsAverage Volume20,281 shsMarket CapitalizationC$769,510.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cotinga Pharmaceuticals Inc. (COT.V) alerts: Email Address Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About Cotinga Pharmaceuticals Inc. (COT.V)Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.Read More COT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COT Stock News HeadlinesMay 1, 2024 | wsj.comKalVista Pharmaceuticals Inc.February 14, 2024 | wsj.comLexicon Pharmaceuticals Inc.November 5, 2023 | morningstar.comAcumen Pharmaceuticals Inc ABOSJuly 22, 2023 | seekingalpha.comSXTP 60 Degrees Pharmaceuticals, Inc.April 28, 2023 | marketwatch.com8-K: ENANTA PHARMACEUTICALS INCFebruary 18, 2023 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationJanuary 24, 2023 | seekingalpha.comPTPI Petros Pharmaceuticals, Inc.October 11, 2022 | wsj.comAmylyx Pharmaceuticals Inc.August 12, 2022 | yahoo.comPepGen Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsMay 26, 2022 | finance.yahoo.comExagen Inc. to Participate in the William Blair 42nd Annual Growth Stock ConferenceSee More Headlines Receive COT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cotinga Pharmaceuticals Inc. (COT.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:COT CUSIPN/A CIKN/A Webcotingapharma.com Phone+1-519-8585157FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow17.50 Book ValueC($0.18) per share Price / Book-0.20Miscellaneous Outstanding Shares21,986,000Free FloatN/AMarket CapC$769,510.00 OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Alison D. SilvaCEO, Pres & DirectorDr. Richard T. Ho (Age 58)Chief Scientific Officer Comp: $323.16kMr. Victor Hugo C.M.A. (Age 51)C.P.A., Chief Financial Officer Mr. Paul PapiVP of Investor RelationsKey CompetitorsPacgen Life Science Co. (PBS.V)CVE:PBSMedifocus Inc. (MFS.V)CVE:MFSSolarvest BioEnergyCVE:SVSPascal BiosciencesCVE:PASiCo TherapeuticsCVE:ICOView All Competitors COT Stock Analysis - Frequently Asked Questions How have COT shares performed in 2024? Cotinga Pharmaceuticals Inc. (COT.V)'s stock was trading at C$0.04 at the start of the year. Since then, COT shares have increased by 0.0% and is now trading at C$0.04. View the best growth stocks for 2024 here. Is Cotinga Pharmaceuticals Inc. (COT.V) a good dividend stock? Cotinga Pharmaceuticals Inc. (COT.V) (CVE:COT) pays an annual dividend of C$0.24 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of Cotinga Pharmaceuticals Inc. (COT.V) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cotinga Pharmaceuticals Inc. (COT.V) investors own include Cascades (CAS), Aurora Cannabis (ACB), Advantage Lithium Corp. (AAL.V) (AAL), InPlay Oil (IPO), Harvest One Cannabis (HVT), Exchange Income (EIF), Datametrex AI (DM), Canadian National Railway (CNI) and Alimentation Couche-Tard (ATD.B). How do I buy shares of Cotinga Pharmaceuticals Inc. (COT.V)? Shares of COT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:COT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cotinga Pharmaceuticals Inc. (COT.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Cotinga Pharmaceuticals Inc. (COT.V) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.